Cedilla: degrading proteins by modulating protein stability

While most protein degradation companies are developing bifunctional molecules that directly induce ubiquitin-mediated degradation, Cedilla is taking a different approach with monovalent small molecules that trigger a broader range of degradation mechanisms.

“The concept of being able to go after it not with the bivalents or bifunctionals but rather with a monovalent program or monovalent compound just seemed incredibly compelling to us,” said Neil Exter from Third Rock Ventures, which launched Cedilla Therapeutics Inc. last year. ...